NBE-Therapeutics

Executive Summary

NBE-Therapeutics is a private Swiss biotechnology company focused on developing next-generation antibody-drug conjugates (ADCs) for the treatment of solid tumors. Founded in 2012 and headquartered in Basel, the company leverages its proprietary in-house platform to create targeted therapies that combine high-affinity antibodies with potent payloads and a novel immune-oncology mechanism. This approach aims to achieve durable anti-tumor responses, potentially improving survival and quality of life for cancer patients. While the company’s pipeline remains undisclosed, its platform is designed to address key limitations of current ADCs, such as off-target toxicity and resistance. NBE-Therapeutics operates in a highly competitive ADC landscape but differentiates itself through a focus on long-lasting immune activation, which could offer a unique therapeutic advantage. Despite limited public information on financing or clinical stage, the company’s innovative technology and strategic location in Basel—a hub for biotech and pharma—position it for potential partnerships or further development. The company’s progress will depend on advancing its lead candidates into preclinical and clinical studies, as well as securing funding or collaborations.

Upcoming Catalysts (preview)

• Q4 2026IND filing for lead ADC candidate40% success
• Q3 2026Preclinical data presentation at major oncology conference70% success
• H1 2027Strategic partnership or licensing deal for platform technology50% success